Intact Protein Analysis Using an Agilent 6550 Q-TOF Mass Spectrometer

Significance of the Topic

The accurate characterization of intact proteins is critical in biopharmaceutical development and quality control. Intact protein mass analysis confirms sequence integrity, identifies post-translational modifications and glycoforms, and provides relative abundance data. High sensitivity and resolution enable rapid verification of therapeutic proteins, ensuring safety and efficacy in drug development and manufacturing.

Study Objectives and Overview

This work demonstrates the application of an Agilent 6550 iFunnel Q-TOF mass spectrometer, coupled with an Agilent 1290 Infinity LC system, for intact protein analysis. Two model proteins—a monoclonal antibody and a therapeutic protein designated P128—were used to assess system performance for mass accuracy, resolution, and sensitivity in characterizing glycoforms and molecular weights.

Methodology and Instrumentation

Sample Preparation:

• Monoclonal antibody diluted to 100 µg/mL in 0.1% formic acid/3% acetonitrile.
• Protein P128 prepared at similar concentration using 0.025% TFA in 3% acetonitrile.
• Injection volume: 1 µL (100 ng protein).

LC Conditions:

• System: Agilent 1290 Infinity.
• Column options: Poroshell 300SB C8 (1.0×75 mm, 5 µm) or ZORBAX RRHD Diphenyl (2.1×100 mm, 1.8 µm).
• Column temperature: 60–80 °C; sample thermostat at 5 °C.
• Mobile phases: A = 0.1% formic acid (or 0.025% TFA) in water; B = 90% acetonitrile with 0.1% formic acid.
• Gradient: 3% B to 90% B over 5 min; total run time 7 min; flow rate 0.4 mL/min.

Mass Spectrometry:

• Agilent 6550 iFunnel Q-TOF with JetStream ESI in positive ion mode.
• Drying gas: 290 °C, 14 L/min; sheath gas: 400 °C, 12 L/min; nebulizer at 20 psi.
• Voltages: capillary 5,000 V; nozzle 2,000 V.

Data Analysis:

• Agilent MassHunter Qualitative Analysis and BioConfirm software for peak modeling, deconvolution, and automated protein confirmation.

Main Results and Discussion

Raw electrospray spectra displayed characteristic charge envelopes for both proteins. Deconvolution produced zero-charge mass spectra:

• Monoclonal antibody: centered at charge state +48; five major glycoforms resolved with accurate masses around 145 kDa.
• Protein P128: deconvoluted mass at 26,490 Da, with minor variants observed at ±15–20 Da.

The high resolution enabled clear separation of glycoform peaks. Automated deconvolution streamlined data processing and reduced analysis time.

Benefits and Practical Applications

• Rapid LC separation (<7 min) with high peak capacity.
• Exceptional Q-TOF sensitivity and mass accuracy for intact proteins.
• Automated software workflows accelerate confirmation of sequence and PTM profiles.
• Applicable to biopharmaceutical QC, comparability studies, and batch release testing.

Future Trends and Possibilities for Application

Advances will focus on increased throughput via multiplexed chromatography, deeper top-down proteomics for detailed PTM mapping, and integration with artificial intelligence for real-time data interpretation. Emerging high-resolution instruments and microflow LC formats will further enhance sensitivity and reduce sample consumption.

Conclusion

The combined Agilent 1290 Infinity LC and 6550 iFunnel Q-TOF platform provides a robust, fast, and sensitive solution for intact protein analysis. The system delivers precise mass measurement, resolves multiple glycoforms, and benefits from automated data processing to support biopharmaceutical research and quality control.